Group 6 Copy 51
0
    Please wait...

    About This Project

    OncoSynergy, Inc.
    The Ebola outbreak in west Africa has been declared a global emergency by the WHO with over 1,000 victims and no approved therapies. OncoSynergy is developing a readily manufactured experimental cancer drug, OS2966, which coincidentally targets the receptor hijacked by ebola to infect cells. This project aims to demonstrate that OS2966 inhibits ebola infection of human cells thus providing the impetus for expediting OS2966 for treatment of ebola.
    Blast off!

    Browse Other Projects on Experiment

    Related Projects

    Prairie falcons – uncertain kinship in an uncertain climate?

    Predicting the effects of climate change on species at the top trophic levels is crucial because they can...

    Amelioration of Alpha-Synuclein in Parkinson's Disease through potentiated protein-protein interactions

    Aggregation of misfolded alpha synuclein protein is a key feature of Parkinson's Disease (PD), which afflicts...

    Understanding Avian Diversity: a genomic approach to determine the relationships of Kingfishers and their allies

    Understanding biodiversity is fundamental to biology. To do so, we need to know the evolutionary tree of...

    Backer Badge Funded

    A biology project funded by 47 people